Roswell Park immunologists identify targetable strategy for reducing solid-tumor cancer metastasis

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A team of scientists led by Scott Abrams at Roswell Park Comprehensive Cancer Center uncovered a pathway associated with metastases to the lung, a common site for cancer spread. The work, just published in JCI Insight, has potentially significant implications that may point to novel cancer therapies.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Artificial intelligence may help radiologists identify subtle signs of breast cancers that are missed during routine mammograms—and some AI systems may even identify patterns associated with an increased risk of cancer before it becomes visible on a mammogram—but there are still many significant limitations, according to a review led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.
Hansoh Pharmaceutical Group announced positive overall survival data from ARTEMIS-008, its pivotal phase III trial in China, evaluating the B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) versus topotecan in patients with relapsed small cell lung cancer whose disease progressed following platinum-based first-line therapy.
Patients with with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations treated with intravenous Rybrevant (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy achieved a median OS of nearly three years (34.3 months), compared with 27.9 months for chemotherapy alone, according to the final overall survival analysis of the phase III PAPILLON study. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login